NEXI
- NexImmune, Inc.
()
Overview
Company Summary
NexImmune, Inc. is a biotechnology company focused on advancing the field of T cell immunotherapy. T cells are a type of white blood cell that play a critical role in the body's immune response. NexImmune aims to harness the power of these cells to help treat various diseases, including cancer and autoimmune disorders.
The company has developed a proprietary technology called AIM� (Artificial Immune Modulation), which allows for the precise manipulation of T cell responses. This technology enables NexImmune to engineer T cells to recognize and attack specific targets, such as tumor cells or diseased tissues.
NexImmune's approach involves the extraction of a patient's own T cells, which are then modified and expanded in the laboratory. The engineered T cells are then reintroduced into the patient's body, where they can effectively target and kill cancer cells or modulate the immune system to treat autoimmune diseases.
One of NexImmune's notable initiatives is its lead product candidate, NEXI-002. This therapy is being developed for the potential treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), two types of blood cancers. NEXI-002 aims to enhance the patient's immune response to destroy tumor cells while minimizing potential side effects.
In addition to their T cell therapy programs, NexImmune also collaborates with various academic institutions and industry partners to advance the development of innovative immunotherapy approaches. The company's ultimate goal is to provide patients with targeted and effective treatments that harness the power of the immune system to fight diseases.